GAITHERSBURG, Md., April 3 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) today announced that it has added two leaders to its senior
commercial management ranks. The new executive appointments are John J.
Trizzino, vice president, trade and distribution, and Mark C. Twyman, vice
president and general manager, vaccines. The addition of Mr. Trizzino and Mr.
Twyman follows several recent senior-level appointments, including three
previously announced leaders on the commercial side of the business.
"We continue to add talent to our world-class management team with the
addition of John and Mark. They bring tremendous experience and capabilities
in the areas of distribution strategy and vaccine commercialization," said
David M. Mott, chief executive officer and president. "These areas are
critical to our future as we work to enhance relationships with our
distributor and wholesaler partners, and to develop the optimal strategy for
global commercialization of our next-generation formulation of FluMist(R)
(Influenza Virus Vaccine Live, Intranasal), which we hope to launch in 2007."
John J. Trizzino has been appointed to the new position of vice president,
trade and distribution. Mr. Trizzino is responsible for developing and
implementing strategies for distribution of MedImmune's current and future
products. He is also responsible for managing relationships with wholesalers
and distributors. Prior to joining MedImmune, Mr. Trizzino was senior vice
president, business development at ID Biomedical. During his tenure at ID
Biomedical, Mr. Trizzino negotiated the company's $2.3 billion U.S. influenza
vaccine distribution agreement and was responsible for government relations in
addition to his business development duties. Previously, he worked for Henry
Schein's medical group for eight years in roles of increasing responsibility,
including vice president, business development, and vice president and general
manager of General Injectables and Vaccines. Mr. Trizzino has more than 24
years of experience in the vaccine industry and has worked closely with public
and private partners including the U.S. Centers for Disease Control and
Prevention, the Department of Health and Human Services and various vaccine
distributors. Mr. Trizzino holds a bachelor of science degree from the C.W.
Post Campus, Long Island University, and a master's in business administration
from New York University's Leonard N. Stern School of Business.
Mark C. Twyman has been appointed to the new position of vice president
and general manager, vaccines. He brings to MedImmune more than 18 years of
biopharmaceutical marketing and sales experience, including 15 years in the
vaccine industry. In his new role, Mr. Twyman is responsible for the
commercial introduction and success of vaccines in MedImmune's portfolio.
Previously, Mr. Twyman worked for Merck's Vaccine Division where he held
positions of increasing responsibility leading to vice president, global
pediatric franchise. Mr. Twyman's experience at Merck included roles in sales
management, marketing, managed care, national accounts, international
marketing and sales as well as overall responsibility for global marketing of
Merck's pediatric vaccines. Mr. Twyman holds a bachelor's degree in economics
from Dickinson College in Carlisle, Pennsylvania. He also earned a master's in
business administration from the Wharton School at the University of
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious disease,
cancer and inflammatory diseases. With more than 2,200 employees worldwide,
MedImmune is headquartered in Maryland. For more information, visit the
company's website at http://www.medimmune.com.
SOURCE MedImmune, Inc.
CONTACT: Media: Clarencia Stephen, +1-301-398-4073, or Kathryn Barrett,
+1-301-398-4320, or Investors: Peter Vozzo, +1-301-398-4358, all of MedImmune,